Mar 16, 2020 / 09:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the DBV Technologies Regulatory Update Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand over the conference to your speaker for today, Sara Sherman, Investor Relations at DBV. You may begin.
Sara Blum Sherman - DBV Technologies S.A. - Senior Director of IR & Strategy
Thank you, Dilem, and thank you all for joining today's call. Earlier today, we issued a press release providing a regulatory update for Viaskin Peanut, our lead product candidate for the treatment of peanut-allergic children 4 to 11 years of age. The press release is available on our website at dbv-technologies.com as well as on the SEC website.
Joining me on the call today are our CEO, Daniel Tassé; and our CMO, Pharis Mohideen. Daniel will deliver remarks, and then we'll open up the call for Q&A.
I would like to note that during our call today, we will make a number of statements that are forward-looking, including but not limited to the company's
DBV Technologies SA - Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years - Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot